<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00627432</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000574179</org_study_id>
    <secondary_id>CLCC-VESUNFIT</secondary_id>
    <secondary_id>RECF0368</secondary_id>
    <secondary_id>SANOFI-AVENTIS-CLCC-VESUNFIT</secondary_id>
    <secondary_id>LILLY-CLCC-VESUNFIT</secondary_id>
    <nct_id>NCT00627432</nct_id>
  </id_info>
  <brief_title>Gemcitabine With Or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Bladder Cancer</brief_title>
  <official_title>Phase 2 Randomized Study Evaluating the Efficacy of Gemcitabine With or Without Oxaliplatin in Patients With Advanced Urothelial Cancer That Cannot be Treated With Cisplatin-based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gemcitabine and oxaliplatin, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying how well giving gemcitabine together with&#xD;
      oxaliplatin works compared to gemcitabine alone in treating patients with locally advanced or&#xD;
      metastatic bladder cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the objective response rate in patients with advanced urothelial cancer&#xD;
           treated with gemcitabine hydrochloride with vs without oxaliplatin.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the tolerance of these regimens in these patients.&#xD;
&#xD;
        -  Determine the overall survival and progression-free survival of patients treated with&#xD;
           these regimens.&#xD;
&#xD;
        -  Determine the quality of life of patients treated with these regimens.&#xD;
&#xD;
        -  Determine the duration of response in patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive gemcitabine hydrochloride IV over 120 minutes on days 1, 8, and&#xD;
           15.&#xD;
&#xD;
        -  Arm II: Patients receive gemcitabine IV over 100 minutes on days 1 and 15 and&#xD;
           oxaliplatin IV over 120 minutes on days 2 and 16.&#xD;
&#xD;
      Treatment in both arms repeats every 4 weeks for up to 6 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <start_date>July 2004</start_date>
  <primary_completion_date type="Anticipated">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as assessed by QLQ-C30 and QLQ-LC13</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Bladder Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed urothelial carcinoma, or transitional cell carcinoma of the&#xD;
             bladder or upper urinary tract&#xD;
&#xD;
               -  Locally advanced disease (T4b) or metastatic disease (N2, N3, or M1)&#xD;
&#xD;
          -  Unable to receive cisplatin-based chemotherapy due to creatinine clearance 30-60&#xD;
             mL/min or performance status 2&#xD;
&#xD;
          -  At least 1 unidimensionally measurable lesion according to RECIST criteria&#xD;
&#xD;
          -  No nonmeasurable lesions only, including any of the following:&#xD;
&#xD;
               -  Ascites&#xD;
&#xD;
               -  Pleural or pericardial effusion&#xD;
&#xD;
               -  Bone metastases&#xD;
&#xD;
               -  Lymphangitis&#xD;
&#xD;
          -  No symptomatic cerebral metastases unless they have been stabilized&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Performance status 0-2&#xD;
&#xD;
          -  ANC ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2 times normal (unless bone metastases are present)&#xD;
&#xD;
          -  Transaminases ≤ 2 times normal (5 times normal if hepatic metastases present)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times normal&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for at least 6 months&#xD;
             after completion of treatment&#xD;
&#xD;
          -  No prior malignancy within the past 5 years except carcinoma in situ of the cervix or&#xD;
             basal cell skin cancer&#xD;
&#xD;
          -  No peripheral neuropathy ≥ grade 2&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No other medical conditions that could interfere with evaluating tolerability,&#xD;
             including any of the following:&#xD;
&#xD;
               -  Congestive heart failure&#xD;
&#xD;
               -  Angina pectoris that cannot be stabilized with medication&#xD;
&#xD;
               -  Myocardial infarction within the past 12 months&#xD;
&#xD;
               -  Serious thromboembolic disease&#xD;
&#xD;
          -  No psychologic, social, or geographic reason that would make follow-up impossible&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior chemotherapy for advanced disease&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy to a target measurable lesion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Damien Pouessel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut du Cancer de Montpellier - Val d'Aurelle</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>February 29, 2008</study_first_submitted>
  <study_first_submitted_qc>February 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2008</study_first_posted>
  <last_update_submitted>October 6, 2010</last_update_submitted>
  <last_update_submitted_qc>October 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2010</last_update_posted>
  <keyword>stage III bladder cancer</keyword>
  <keyword>stage IV bladder cancer</keyword>
  <keyword>transitional cell carcinoma of the bladder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

